Intero Biosystems wants drugmakers to test on mini human intestines, not animals
- ID
- 35592
- Status
- summarized
- Published
- 15 Oct 2026, 7:00 AM
- Fetched
- 15 Oct 2026, 7:34 AM
- Provider
- TechCrunch
- Category
- technology
- Original URL
- https://techcrunch.com/2026/10/14/intero-biosystems-wants-drugmakers-to-test-on-mini-human-intestines-not-animals/
- Source URL
- https://techcrunch.com/feed/
Summary
- Score
- 2.0
- Created
- 15 Oct 2026, 7:35 AM
- Tags
- Audience
- -
What happened
Intero Biosystems, a Denver-based startup spun out of the University of Michigan, sells GastroScreen — human intestinal organoids, lab-grown gut tissue about one millimeter across, shipped roughly 100 at a time in a tube — to pharmaceutical, biotech, food, and chemical companies as a supplement or alternative to animal testing. It also sells the supporting supplies (nutrient mixes that feed the cells, chemicals used in experiments) and runs studies for customers. Co-founder and CTO Madeline Eiken says the organoids contain multiple cell and tissue types found in the human intestine, arguing that most drugs fail clinical trials and that animal models and flat cell layers are not human-relevant.
Why it matters
This is a biotech lab-supply and contract-research story with no stated price, no software, no API, no Malaysian or Southeast Asian angle, and nothing a developer, AI/ML learner, or SaaS founder would have to change. The only concrete operational detail worth noting is the logistics claim — living tissue shipped by mail in batches of ~100 one-millimeter organoids — which is a hard-tech fulfilment problem, not a tooling one. Skip it for this audience unless someone in the room specifically works in life sciences.
Discussion angle
Optional 60-second mention: is there anything transferable from 'shipping mini living organs in the mail' to how we think about physical-product fulfilment for software-adjacent startups — or is this simply outside the community's scope?